Related Experiment Video

Updated: May 10, 2026

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis
09:43

In vivo Near Infrared Fluorescence NIRF Intravascular Molecular Imaging of Inflammatory Plaque, a Multimodal Approach to Imaging of Atherosclerosis

Published on: August 4, 2011

18.1K

Recent Advances of Aggregation-Induced Emission Luminogens in Atherosclerotic Cardiovascular Disease

Yue Lan1, Sheng'e Su1, Jiageng Cai2

  • 1The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, State Key Laboratory of Vascular Homeostasis and Remodeling, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University, Beijing, 100191, China.

Advanced Healthcare Materials
|September 4, 2025
PubMed

Insights

Aggregation-induced emission luminogens (AIEgens) show promise for diagnosing and treating atherosclerotic cardiovascular disease (ASCVD). This review highlights AIEgen properties and applications in ASCVD sensing, imaging, and therapy.

Area of Science:

  • * Nanotechnology and Materials Science
  • * Biomedical Engineering
  • * Medicinal Chemistry

Background:

  • * Atherosclerotic cardiovascular disease (ASCVD) is a leading global cause of mortality.
  • * Plaque development involves lipid accumulation in artery walls, leading to severe complications.
  • * Novel diagnostic and therapeutic agents are crucial for managing ASCVD.

Purpose of the Study:

  • * To review recent advancements in aggregation-induced emission luminogens (AIEgens) for ASCVD.
  • * To explore AIEgen properties and their design for ASCVD management.
  • * To summarize AIEgen applications in ASCVD biomarker sensing, imaging, and treatment.

Main Methods:

  • * Systematic literature review of AIEgen research in ASCVD (last five years).
  • * Analysis of AIEgen characteristics: fluorescence, photostability, biocompatibility.
  • * Evaluation of AIEgen applications in sensing, imaging, and therapy.

Main Results:

  • * AIEgens exhibit enhanced fluorescence in aggregated states, ideal for biomedical applications.
  • * Tailored AIEgen designs facilitate effective ASCVD biomarker detection and imaging.
  • * AIEgens demonstrate potential in therapeutic strategies for ASCVD.

Conclusions:

  • * AIEgens represent a promising class of materials for ASCVD diagnosis and treatment.
  • * Further research is needed to address current challenges and optimize AIEgen utility.
  • * Future prospects include enhanced AIEgen development for comprehensive ASCVD management.

Keywords:
aggregation‐induced emission luminogensatherosclerotic cardiovascular diseasebiomarker sensingdiagnosis and treatment

More Related Videos

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis08:01

Synthesis of Monocyte-targeting Peptide Amphiphile Micelles for Imaging of Atherosclerosis

Published on: November 17, 2017

7.4K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.4K

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...